These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
122 related items for PubMed ID: 15667487
21. Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. Van Thiel DH, Carroll P, Abu-Elmagd K, Rodriguez-Rilo H, Irish W, McMichael J, Starzl TE. Am J Gastroenterol; 1995 Mar; 90(3):455-9. PubMed ID: 7532912 [Abstract] [Full Text] [Related]
22. Use of mycophenolate mofetil in the treatment of primary sclerosing cholangitis. Lankarani KB. J Clin Gastroenterol; 2003 Jan; 36(1):86. PubMed ID: 12488723 [No Abstract] [Full Text] [Related]
24. Use of mycophenolate mofetil in resistant membranous nephropathy. Miller G, Zimmerman R, Radhakrishnan J, Appel G. Am J Kidney Dis; 2000 Aug; 36(2):250-6. PubMed ID: 10922302 [Abstract] [Full Text] [Related]
25. Effect of mycophenolate mofetil on cerulein-induced acute pancreatitis. Tasdogan B, Kucuk HF, Kurt N, Kaptanoglu L, Uzun H, Eser M. Eur Surg Res; 2010 Aug; 45(3-4):146-50. PubMed ID: 20924190 [Abstract] [Full Text] [Related]
26. Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis: a pilot study. Lindor KD, Jorgensen RA, Anderson ML, Gores GJ, Hofmann AF, LaRusso NF. Am J Gastroenterol; 1996 Mar; 91(3):511-5. PubMed ID: 8633500 [Abstract] [Full Text] [Related]
27. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study. Tabibian JH, Weeding E, Jorgensen RA, Petz JL, Keach JC, Talwalkar JA, Lindor KD. Aliment Pharmacol Ther; 2013 Mar; 37(6):604-12. PubMed ID: 23384404 [Abstract] [Full Text] [Related]
28. Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active Crohn's disease? Miehsler W, Reinisch W, Moser G, Gangl A, Vogelsang H. Am J Gastroenterol; 2001 Mar; 96(3):782-7. PubMed ID: 11280551 [Abstract] [Full Text] [Related]
29. Mycophenolate mofetil for the treatment of scleritis. Sen HN, Suhler EB, Al-Khatib SQ, Djalilian AR, Nussenblatt RB, Buggage RR. Ophthalmology; 2003 Sep; 110(9):1750-5. PubMed ID: 13129873 [Abstract] [Full Text] [Related]
30. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years. Grinyó JM, Gil-Vernet S, Cruzado JM, Caldés A, Riera L, Serón D, Rama I, Torras J. Transpl Int; 2003 Nov; 16(11):820-7. PubMed ID: 12879230 [Abstract] [Full Text] [Related]
31. Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial. Piepers S, Van den Berg-Vos R, Van der Pol WL, Franssen H, Wokke J, Van den Berg L. Brain; 2007 Aug; 130(Pt 8):2004-10. PubMed ID: 17626040 [Abstract] [Full Text] [Related]
32. Prospective Clinical Trial of Rifaximin Therapy for Patients With Primary Sclerosing Cholangitis. Tabibian JH, Gossard A, El-Youssef M, Eaton JE, Petz J, Jorgensen R, Enders FB, Tabibian A, Lindor KD. Am J Ther; 2017 Aug; 24(1):e56-e63. PubMed ID: 24914504 [Abstract] [Full Text] [Related]
34. Conversion to mycophenolate mofetil for modulating recurrent hepatitis C in liver transplant recipients. Kornberg A, Küpper B, Wilberg J, Tannapfel A, Thrum K, Bärthel E, Hommann M, Settmacher U. Transpl Infect Dis; 2007 Dec; 9(4):295-301. PubMed ID: 17511824 [Abstract] [Full Text] [Related]
35. Mycophenolate mofetil for primary biliary cirrhosis and sclerosis cholangitis? Altschuler EL. Nephrol Dial Transplant; 1999 Mar; 14(3):798-9. PubMed ID: 10193850 [No Abstract] [Full Text] [Related]
37. The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis. Trauner M, Gulamhusein A, Hameed B, Caldwell S, Shiffman ML, Landis C, Eksteen B, Agarwal K, Muir A, Rushbrook S, Lu X, Xu J, Chuang JC, Billin AN, Li G, Chung C, Subramanian GM, Myers RP, Bowlus CL, Kowdley KV. Hepatology; 2019 Sep; 70(3):788-801. PubMed ID: 30661255 [Abstract] [Full Text] [Related]
38. Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis. Hu W, Liu Z, Chen H, Tang Z, Wang Q, Shen K, Li L. Chin Med J (Engl); 2002 May; 115(5):705-9. PubMed ID: 12133539 [Abstract] [Full Text] [Related]
39. Long-term efficacy and tolerability of mycophenolate mofetil therapy in diffuse scleroderma skin disease. Boulos D, Ngian GS, Rajadurai A, Elford K, Stevens W, Proudman S, Owen C, Roddy J, Nikpour M, Youssef P, Hill C, Sahhar J. Int J Rheum Dis; 2017 Apr; 20(4):481-488. PubMed ID: 28337853 [Abstract] [Full Text] [Related]
40. Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy. Majithia V, Harisdangkul V. Rheumatology (Oxford); 2005 Mar; 44(3):386-9. PubMed ID: 15572389 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]